CTOs on the Move

Rhythm Pharmaceuticals

www.rhythmtx.com

 
Rhythm is a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity.
  • Number of Employees: 100-250
  • Annual Revenue: $1-10 Million
  • www.rhythmtx.com
  • 222 Berkeley Street 12th Floor
    Boston, MA USA 02116
  • Phone: 857.264.4280

Executives

Name Title Contact Details
Taylor Cucchiara
Associate Director, Cybersecurity Profile

Funding

Rhythm Pharmaceuticals raised $41M on 02/17/2017
Rhythm Pharmaceuticals raised $37.5M on 06/16/2022

Similar Companies

Magen BioSciences Inc

Magen BioSciences Inc is a Waltham, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Chiral Quest

Chiral Quest is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Viacor

Viacor Inc. is a Wilmington, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AOBiome

AOBiome LLC is developing first-in-class topical biologics for the treatment of inflammatory skin conditions. We have developed extensive scientific and manufacturing expertise on the use of beneficial ammonia-oxidizing bacteria (AOB). AOB are naturally occurring bacteria that metabolize the ammonia found in sweat, creating both nitrite and nitric oxide, with both anti-inflammatory and anti-infective properties. The therapeutic potential of nitrite and nitric oxide are widely recognized, although as yet, largely unrealized as delivery, let alone targeted delivery is extremely difficult. The company`s proprietary AOB offers the potential of a first-in-class natural delivery system for nitrite and nitric oxide.

Antibe Therapeutics

Antibe Therapeutics develops safer medications for chronic pain and inflammation. Today, physicians and consumers rely principally on non-steroidal anti-inflammatory drugs (NSAIDs), a $12 billion category of medications that includes brands like Advil, Aleve, Motrin, Celebrex, Voltaren and Aspirin. While effective, NSAIDs can cause gastrointestinal damage and bleeding. To address this serious medical need, Antibe has patented a technology for linking NSAID molecules to hydrogen sulfide molecules. More than a decade of academic and applied research has demonstrated that hydrogen sulfide, when appropriately delivered, can protect the gastrointestinal tract and enhance the anti-inflammatory effectiveness of today’s NSAIDs. Beginning with its IPO in mid-2013, Antibe has raised more than $10 million and initiated human clinical trials of its first drug, aimed at mild to moderate pain.